TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical has announced a series of continuing connected transactions, including the CQ Pharma Mutual Supply Framework Agreement, the Framework Tenancy Agreements, and the Fosun International Mutual Supply Framework Agreement. These agreements, set to commence in 2026, involve mutual supply and leasing arrangements with CQ Pharma Holdings and Fosun International, highlighting Fosun Pharma’s strategic partnerships and operational expansions. The transactions are structured to comply with Hong Kong Listing Rules, ensuring they are conducted on normal commercial terms and are in the interests of the company and its shareholders.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products and services, with a market presence that includes a variety of connected transactions and partnerships.
Average Trading Volume: 7,318,611
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.92B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.